MedElevator
Войти в исследования Abdominal radiology (New York) · 2025
Localization of PSMA-avid lesions on PSMA PET-CT on prostate MRI in patients with PI-RADS 3.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Takahashi Hiroaki, Nakai Hirotsugu, Ballman Karla V, Lomas Derek J, Mynderse Lance A, Kawashima Akira, Huang Steve, Legout Jordan D, Young Jason R, Thorpe Mattew P, Johnson Geoffrey B, Karnes R Jeffrey, Sartor Alton O, Takahashi Naoki
Аннотация
PURPOSE: To localize PSMA-avid lesions identified by PSMA PET-CT on separately performed prostate MRI and evaluate imaging findings on fused PET-CT/MRI.
METHODS: Patients without prior history of clinically significant prostate cancer (csPCa: Gleason score [GS] 3 + 4 or higher) who had (1) PI-RADS 3 on prostate MRI between 2021 and 2023, (2) MRI/US fusion targeted biopsy for PI-RADS 3 lesion(s) and systemic biopsy, and (3) subsequent PSMA PET-CT were identified. PSMA PET-CT images were fused onto prostate MRI. PI-RADS 3 lesions were categorized by PRIMARY score. Discordant PSMA-avid lesions with PRIMARY scores 2-5 outside of PI-RADS 3 lesions were identified. Fisher's exact test was used to compare the proportion of csPCa on targeted biopsy between PSMA-positive (PRIMARY score 3 or more) and PSMA-negative (PRIMARY score 1 or 2) PI-RADS 3 lesions. P < 0.05 was considered statistically significant.
RESULTS: 30 patients (mean age 67 years) with 38 PI-RADS 3 lesions were identified. 29 patients had csPCa, and one patient had GS 6. 22 PI-RADS 3 lesions were PSMA-positive (PRIMARY score 3 or more), of which 18 (81.8%) were csPCa on targeted biopsy; 16 PI-RADS 3 lesions were PSMA-negative, of which 4 (25.0%) were csPCa on targeted biopsy (p < 0.001). Sensitivity and specificity for the presence of csPCa on targeted biopsy was 81.8% and 75.0%. Out of 30 patients, 12 (40.0%) had 16 discordant PSMA-avid (PRIMARY score 2 or more) lesions and 10 patients had 10 discordant PSMA-positive lesions outside PI-RADS 3 lesions In 5 of those 12 (41.7%), discordant PSMA-avid lesions had higher PRIMARY score than PI-RADS 3 lesions. In 4 of those 5 (80%), systemic biopsy showed higher GS than targeted biopsy.
CONCLUSION: Lesion-level analysis showed PSMA-positive PI-RADS 3 lesions had higher probability of csPCa than PSMA-negative PI-RADS 3 lesions. Discordant PSMA-avid lesions with higher PRIMARY score than that of PI-RADS 3 lesions often represented another more aggressive focus not initially identified on MRI.
METHODS: Patients without prior history of clinically significant prostate cancer (csPCa: Gleason score [GS] 3 + 4 or higher) who had (1) PI-RADS 3 on prostate MRI between 2021 and 2023, (2) MRI/US fusion targeted biopsy for PI-RADS 3 lesion(s) and systemic biopsy, and (3) subsequent PSMA PET-CT were identified. PSMA PET-CT images were fused onto prostate MRI. PI-RADS 3 lesions were categorized by PRIMARY score. Discordant PSMA-avid lesions with PRIMARY scores 2-5 outside of PI-RADS 3 lesions were identified. Fisher's exact test was used to compare the proportion of csPCa on targeted biopsy between PSMA-positive (PRIMARY score 3 or more) and PSMA-negative (PRIMARY score 1 or 2) PI-RADS 3 lesions. P < 0.05 was considered statistically significant.
RESULTS: 30 patients (mean age 67 years) with 38 PI-RADS 3 lesions were identified. 29 patients had csPCa, and one patient had GS 6. 22 PI-RADS 3 lesions were PSMA-positive (PRIMARY score 3 or more), of which 18 (81.8%) were csPCa on targeted biopsy; 16 PI-RADS 3 lesions were PSMA-negative, of which 4 (25.0%) were csPCa on targeted biopsy (p < 0.001). Sensitivity and specificity for the presence of csPCa on targeted biopsy was 81.8% and 75.0%. Out of 30 patients, 12 (40.0%) had 16 discordant PSMA-avid (PRIMARY score 2 or more) lesions and 10 patients had 10 discordant PSMA-positive lesions outside PI-RADS 3 lesions In 5 of those 12 (41.7%), discordant PSMA-avid lesions had higher PRIMARY score than PI-RADS 3 lesions. In 4 of those 5 (80%), systemic biopsy showed higher GS than targeted biopsy.
CONCLUSION: Lesion-level analysis showed PSMA-positive PI-RADS 3 lesions had higher probability of csPCa than PSMA-negative PI-RADS 3 lesions. Discordant PSMA-avid lesions with higher PRIMARY score than that of PI-RADS 3 lesions often represented another more aggressive focus not initially identified on MRI.